AR080792A1 - Compuesto de 1-acetil-indol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para la inhibicion de la actividad de perk y para tratar o reducir la gravedad del cancer y otras dolencias. - Google Patents
Compuesto de 1-acetil-indol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para la inhibicion de la actividad de perk y para tratar o reducir la gravedad del cancer y otras dolencias.Info
- Publication number
- AR080792A1 AR080792A1 ARP110100955A ARP110100955A AR080792A1 AR 080792 A1 AR080792 A1 AR 080792A1 AR P110100955 A ARP110100955 A AR P110100955A AR P110100955 A ARP110100955 A AR P110100955A AR 080792 A1 AR080792 A1 AR 080792A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fluoro
- substituents independently
- independently selected
- iodo
- Prior art date
Links
- UUCUQJHYUPXDHN-UHFFFAOYSA-N N-Acetylindole Chemical compound C1=CC=C2N(C(=O)C)C=CC2=C1 UUCUQJHYUPXDHN-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 230000005484 gravity Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 23
- -1 -OH Chemical group 0.000 abstract 13
- 125000001153 fluoro group Chemical group F* 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 abstract 2
- 108091008010 PERKs Proteins 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000002346 iodo group Chemical group I* 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31747610P | 2010-03-25 | 2010-03-25 | |
| US35286310P | 2010-06-09 | 2010-06-09 | |
| US38148010P | 2010-09-10 | 2010-09-10 | |
| US38815110P | 2010-09-30 | 2010-09-30 | |
| US41906810P | 2010-12-02 | 2010-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080792A1 true AR080792A1 (es) | 2012-05-09 |
Family
ID=46160738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100955A AR080792A1 (es) | 2010-03-25 | 2011-03-23 | Compuesto de 1-acetil-indol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para la inhibicion de la actividad de perk y para tratar o reducir la gravedad del cancer y otras dolencias. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120077828A1 (enExample) |
| EP (1) | EP2549868B1 (enExample) |
| JP (1) | JP5876031B2 (enExample) |
| KR (1) | KR101676077B1 (enExample) |
| CN (1) | CN102917588B (enExample) |
| AR (1) | AR080792A1 (enExample) |
| AU (1) | AU2011232516B2 (enExample) |
| EA (1) | EA022325B1 (enExample) |
| ES (1) | ES2530955T3 (enExample) |
| IL (1) | IL222120A (enExample) |
| MX (1) | MX2012011045A (enExample) |
| SG (1) | SG183954A1 (enExample) |
| TW (1) | TW201202241A (enExample) |
| UY (1) | UY33288A (enExample) |
| WO (1) | WO2011119663A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012024380A2 (pt) * | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
| WO2012158123A1 (en) * | 2011-05-13 | 2012-11-22 | Agency For Science, Technology And Research | Compounds and methods for treating insulin resistance syndrome |
| LT2734522T (lt) | 2011-07-19 | 2019-02-11 | Merck Sharp & Dohme B.V. | 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| TWI498325B (zh) * | 2013-01-18 | 2015-09-01 | Hoffmann La Roche | ３－取代吡唑及其用途 |
| AU2014247215B2 (en) * | 2013-04-04 | 2018-05-10 | Janssen Pharmaceutica Nv | Novel N-(2,3-dihydro-1H-pyrrolo[2,3-b]jpyridin-5-yl)-4- quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4- quinazolinamine derivatives as perk inhibitors |
| TWI482757B (zh) * | 2013-10-07 | 2015-05-01 | Luminescence Technology Corp | Ｖｅｇｆ－２／３受體及蛋白質酪胺酸激酶抑制劑及其醫藥用途 |
| WO2015056180A1 (en) * | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| EP3076974A1 (en) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| WO2015136463A1 (en) * | 2014-03-11 | 2015-09-17 | Glaxosmithkline Intellectual Property (No.2) Limited | Chemical compounds acting as perk inhibitors |
| WO2015181633A2 (en) | 2014-04-11 | 2015-12-03 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| US9949971B2 (en) | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
| US20170231986A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor |
| PE20190710A1 (es) * | 2014-10-24 | 2019-05-17 | Bristol Myers Squibb Co | Compuestos de indol carboxamida utiles como inhibidores de cinasas |
| PL3218378T3 (pl) | 2014-11-14 | 2020-10-19 | Nerviano Medical Sciences S.R.L. | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych |
| WO2016126026A2 (ko) * | 2015-02-04 | 2016-08-11 | 서울대학교병원 | 당뇨병 치료 조성물 및 이의 용도 |
| LT3317281T (lt) | 2015-07-02 | 2020-07-27 | Acerta Pharma B.V. | (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamido kompozicijų kietosios formos |
| TW201722957A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產（第二）有限公司 | 化學化合物 |
| WO2017046739A1 (en) * | 2015-09-15 | 2017-03-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Imidazolidinone derivatives as inhibitors of perk |
| ES2921855T3 (es) * | 2016-04-07 | 2022-09-01 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| ES2886587T3 (es) * | 2016-04-15 | 2021-12-20 | Cancer Research Tech Ltd | Compuestos heterocíclicos como inhibidores de la quinasa RET |
| US11026945B2 (en) * | 2016-04-29 | 2021-06-08 | The Trustees Of The University Of Pennsylvania | Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation |
| WO2017216792A1 (en) | 2016-06-13 | 2017-12-21 | Ramot At Tel-Aviv University Ltd. | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins |
| EP3472165B1 (en) | 2016-06-21 | 2023-09-06 | Nerviano Medical Sciences S.r.l. | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
| WO2018015879A1 (en) * | 2016-07-20 | 2018-01-25 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| WO2018055578A1 (en) * | 2016-09-22 | 2018-03-29 | The University Of Hong Kong | Preventive and therapeutic approach for aberrant cell differentiation and isr-associated diseases |
| US20190388426A1 (en) | 2017-01-30 | 2019-12-26 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| CN106974910B (zh) * | 2017-03-02 | 2019-11-12 | 深圳大学 | 含索拉非尼和gsk2656157的药物组合物及用途 |
| CN106963769B (zh) * | 2017-03-03 | 2019-10-25 | 深圳大学 | 含pi3k抑制剂和perk抑制剂的药物组合物及其应用 |
| JP6637217B2 (ja) | 2017-03-06 | 2020-01-29 | 株式会社坪田ラボ | 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法 |
| KR102007135B1 (ko) * | 2017-03-20 | 2019-08-02 | 포르마 세라퓨틱스 인크. | 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물 |
| WO2019021208A1 (en) * | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| AU2018358160B2 (en) | 2017-11-02 | 2023-03-16 | Abbvie Inc. | Modulators of the integrated stress pathway |
| CN108003163B (zh) * | 2017-11-30 | 2020-11-24 | 武汉九州钰民医药科技有限公司 | 用作激酶抑制剂的吡唑并嘧啶类化合物及其应用 |
| CN111100130B (zh) * | 2018-10-29 | 2022-07-15 | 四川大学 | 4-氨基吡咯并嘧啶衍生物及其制备方法和用途 |
| CN111213632B (zh) * | 2019-11-19 | 2022-03-01 | 长春中医药大学 | 动物药环氧树脂标本制作方法 |
| WO2021252488A1 (en) | 2020-06-08 | 2021-12-16 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022212326A1 (en) | 2021-03-29 | 2022-10-06 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| EP4320127A1 (en) | 2021-04-05 | 2024-02-14 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2023034236A1 (en) * | 2021-08-31 | 2023-03-09 | Wisconsin Alumni Research Foundation | Deuterated inhibitors of rip kinases |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2566158A1 (en) * | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| WO2005121142A1 (en) * | 2004-06-11 | 2005-12-22 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer |
| JP2009514899A (ja) * | 2005-11-04 | 2009-04-09 | スミスクライン ビーチャム コーポレーション | チエノピリジンＢ−Ｒａｆキナーゼ阻害剤 |
| AU2007272330A1 (en) * | 2006-07-13 | 2008-01-17 | Zymogenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| WO2009151621A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| JP5746032B2 (ja) * | 2008-09-19 | 2015-07-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ３，４−ジヒドロ−２Ｈ−ピロロ［１，２−ａ］ピラジン−１−オン誘導体 |
-
2011
- 2011-03-22 UY UY0001033288A patent/UY33288A/es not_active Application Discontinuation
- 2011-03-23 EA EA201290952A patent/EA022325B1/ru not_active IP Right Cessation
- 2011-03-23 EP EP11760102.1A patent/EP2549868B1/en active Active
- 2011-03-23 KR KR1020127027705A patent/KR101676077B1/ko not_active Expired - Fee Related
- 2011-03-23 TW TW100109800A patent/TW201202241A/zh unknown
- 2011-03-23 AU AU2011232516A patent/AU2011232516B2/en not_active Ceased
- 2011-03-23 CN CN201180025962.7A patent/CN102917588B/zh not_active Expired - Fee Related
- 2011-03-23 MX MX2012011045A patent/MX2012011045A/es active IP Right Grant
- 2011-03-23 AR ARP110100955A patent/AR080792A1/es not_active Application Discontinuation
- 2011-03-23 US US13/069,569 patent/US20120077828A1/en not_active Abandoned
- 2011-03-23 SG SG2012066379A patent/SG183954A1/en unknown
- 2011-03-23 JP JP2013501421A patent/JP5876031B2/ja not_active Expired - Fee Related
- 2011-03-23 WO PCT/US2011/029511 patent/WO2011119663A1/en not_active Ceased
- 2011-03-23 ES ES11760102T patent/ES2530955T3/es active Active
-
2012
- 2012-09-24 IL IL222120A patent/IL222120A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102917588A (zh) | 2013-02-06 |
| KR20130018272A (ko) | 2013-02-20 |
| EA022325B1 (ru) | 2015-12-30 |
| CN102917588B (zh) | 2014-10-08 |
| JP2013534902A (ja) | 2013-09-09 |
| EA201290952A1 (ru) | 2013-04-30 |
| AU2011232516B2 (en) | 2014-08-07 |
| TW201202241A (en) | 2012-01-16 |
| UY33288A (es) | 2011-10-31 |
| KR101676077B1 (ko) | 2016-11-14 |
| EP2549868A1 (en) | 2013-01-30 |
| AU2011232516A1 (en) | 2012-10-04 |
| EP2549868B1 (en) | 2015-01-07 |
| MX2012011045A (es) | 2012-11-16 |
| WO2011119663A8 (en) | 2012-10-26 |
| ES2530955T3 (es) | 2015-03-09 |
| US20120077828A1 (en) | 2012-03-29 |
| WO2011119663A1 (en) | 2011-09-29 |
| IL222120A (en) | 2015-09-24 |
| JP5876031B2 (ja) | 2016-03-02 |
| EP2549868A4 (en) | 2013-08-07 |
| SG183954A1 (en) | 2012-10-30 |
| AU2011232516A8 (en) | 2012-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080792A1 (es) | Compuesto de 1-acetil-indol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para la inhibicion de la actividad de perk y para tratar o reducir la gravedad del cancer y otras dolencias. | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| MX2015011245A (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
| PE20130601A1 (es) | Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa | |
| DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| NZ739339A (en) | Apoptosis signal-regulating kinase inhibitor | |
| GEP201706778B (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| EA201492125A1 (ru) | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| CO6710915A2 (es) | Composiciones farmacéuticas que contienen un inhibidor de dgat1 ácido 4-(4-(5-6(- trifluorometil-piridin -3- ilamino)-piridin- 2-il)fenil)cicloheiyl)-acético o sales del mismo | |
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| CU24330B1 (es) | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
| EP2588106A4 (en) | DELAYED RELEASED PHARMACEUTICAL COMPOSITION WITH PRAMIPEXOL OR A PHARMACEUTICALLY ALLOWED SALT AND INCREASED STABILITY | |
| UY33191A (es) | Derivados de pirazina | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |